AIM IMMUNOTECH INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
AIM IMMUNOTECH INC. (AIM) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $199.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-08-07
- AIM IMMUNOTECH INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-06-30 was $199.00K.
- AIM IMMUNOTECH INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2024-06-30 was $2.50M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month |
|---|---|
| 2026-06-30 | $199.00K 10-Q · filed 2026-08-07 |
| 2024-06-30 | $2.50M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |